169 related articles for article (PubMed ID: 32546835)
1. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
Pickles OJ; Lee LYW; Starkey T; Freeman-Mills L; Olsson-Brown A; Cheng V; Hughes DJ; Lee A; Purshouse K; Middleton G
Br J Cancer; 2020 Sep; 123(5):691-693. PubMed ID: 32546835
[TBL] [Abstract][Full Text] [Related]
2. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Maio M; Hamid O; Larkin J; Covre A; Altomonte M; Calabrò L; Vardhana SA; Robert C; Ibrahim R; Anichini A; Wolchok JD; Giacomo AMD
Clin Cancer Res; 2020 Aug; 26(16):4201-4205. PubMed ID: 32540850
[TBL] [Abstract][Full Text] [Related]
4. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
Chang HL; Wei PJ; Wu KL; Huang HL; Yang CJ
Lung Cancer; 2020 Aug; 146():376-377. PubMed ID: 32576385
[No Abstract] [Full Text] [Related]
6. Liver transplant immunosuppression during the covid-19 pandemic.
Forns X; Navasa M
Gastroenterol Hepatol; 2020 Oct; 43(8):457-463. PubMed ID: 32646657
[TBL] [Abstract][Full Text] [Related]
7. Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists.
Zahedi Niaki O; Anadkat MJ; Chen ST; Fox LP; Harp J; Micheletti RG; Nambudiri VE; Pasieka HB; Shinohara MM; Rosenbach M; Merola JF
J Am Acad Dermatol; 2020 Oct; 83(4):1150-1159. PubMed ID: 32569797
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
Chu C; Sun Y; Pan Y
Oral Oncol; 2020 Aug; 107():104860. PubMed ID: 32571643
[No Abstract] [Full Text] [Related]
9. Immune status could determine efficacy of COVID-19 therapies.
Cully M
Nat Rev Drug Discov; 2020 Jul; 19(7):431-434. PubMed ID: 32546768
[No Abstract] [Full Text] [Related]
10. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
Weiskopf D; Schmitz KS; Raadsen MP; Grifoni A; Okba NMA; Endeman H; van den Akker JPC; Molenkamp R; Koopmans MPG; van Gorp ECM; Haagmans BL; de Swart RL; Sette A; de Vries RD
Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32591408
[TBL] [Abstract][Full Text] [Related]
11. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
Front Immunol; 2020; 11():1059. PubMed ID: 32477373
[TBL] [Abstract][Full Text] [Related]
12. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Am Acad Dermatol; 2020 Sep; 83(3):e251-e252. PubMed ID: 32534081
[No Abstract] [Full Text] [Related]
13. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
Ledford H
Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
[No Abstract] [Full Text] [Related]
14. COVID-19: consider cytokine storm syndromes and immunosuppression.
Mehta P; McAuley DF; Brown M; Sanchez E; Tattersall RS; Manson JJ;
Lancet; 2020 Mar; 395(10229):1033-1034. PubMed ID: 32192578
[No Abstract] [Full Text] [Related]
15. Uneventful Course in Patients With Inflammatory Bowel Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak in Northern Italy.
Norsa L; Indriolo A; Sansotta N; Cosimo P; Greco S; D'Antiga L
Gastroenterology; 2020 Jul; 159(1):371-372. PubMed ID: 32247695
[No Abstract] [Full Text] [Related]
16. Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic.
Kearns DG; Chat VS; Uppal S; Wu JJ
J Am Acad Dermatol; 2020 Dec; 83(6):e433-e434. PubMed ID: 32735966
[No Abstract] [Full Text] [Related]
17. When a global pandemic complicates cancer care: Although oncologists and their patients are accustomed to fighting tough battles against a lethal disease, Coronavirus Disease 2019 (COVID-19) has posed an unprecedented challenge.
Printz C
Cancer; 2020 Jul; 126(14):3171-3173. PubMed ID: 32584455
[No Abstract] [Full Text] [Related]
18. Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era.
Arpino G; De Angelis C; De Placido P; Pietroluongo E; Formisano L; Bianco R; Fiore G; Montella E; Forestieri V; Lauria R; Cardalesi C; Vozzella EA; Iervolino A; Giuliano M; De Placido S
ESMO Open; 2020 Sep; 5(5):e000885. PubMed ID: 32958531
[TBL] [Abstract][Full Text] [Related]
19. Complement as a target in COVID-19?
Risitano AM; Mastellos DC; Huber-Lang M; Yancopoulou D; Garlanda C; Ciceri F; Lambris JD
Nat Rev Immunol; 2020 Jun; 20(6):343-344. PubMed ID: 32327719
[TBL] [Abstract][Full Text] [Related]
20. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]